Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Varlilumab Biosimilar - Anti-CD27, TNFRSF7 mAb - Research Grade |
---|---|
Source | CAS 1393344-72-3 |
Species | Homo sapiens |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Varlilumab,1F5,CDX-1127,CD27, TNFRSF7,anti-CD27, TNFRSF7 |
Reference | PX-TA1352 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Varlilumab has been investigated for the treatment of Melanoma, Skin Ulcer, Burkett’s Lymphoma, Mantle cell lymphoma, and T-cell Malignancy.
Varlilumab Biosimilar - Anti-CD27, TNFRSF7 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Related products
Reviews
Il n’y a pas encore d’avis.